What does the evidence say about Creatine Fatigue Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Creatine Fatigue Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Conclusions Creatine supplementation at 6 g/day was associated with improvements in fatigue and peripheral muscle strength in patients with PCC, with a favorable safety profile. [Dos Santos MSC (2026); evidence level 2] - Background Post-COVID-19 condition (PCC) is characterized by fatigue, dyspnea, and muscle pain, with treatment including physical exercise and nutritional support. [Dos Santos MSC (2026); evidence level 2] - Creatine supplementation under these conditions may increase the total body creatine pool, thereby increasing muscular phosphocreatine availability and improving the energy substrate supply to sustain activity and reduce fatigue. [Dos Santos MSC (2026); evidence level 2] - It serves as a critical energy source during high-intensity, short-duration activities, such as weightlifting and sprinting, by replenishing adenosine triphosphate (ATP) stores, contributing to improvements in muscle strength, endurance, and volumization, as well as increased fat-free mass and muscle morphology []. [Muacevic Alexander (2026); evidence level 2] - This, in turn, may contribute to improved muscle performance and hypertrophy over the training period []. [Muacevic Alexander (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.